Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Radiol. Mar 28, 2016; 8(3): 308-315
Published online Mar 28, 2016. doi: 10.4329/wjr.v8.i3.308
Published online Mar 28, 2016. doi: 10.4329/wjr.v8.i3.308
Angiographic and volumetric effects of mammalian target of rapamycin inhibitors on angiomyolipomas in tuberous sclerosis
Rahul A Sheth, Department of Interventional Radiology, MD Anderson Cancer Center, Houston, TX 77030, United States
Adam S Feldman, Department of Urology, Massachusetts General Hospital, Boston, MA 02114, United States
Elahna Paul, Department of Pediatric Nephrology, Massachusetts General Hospital, Boston, MA 02114, United States
Elizabeth A Thiele, Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, United States
T Gregory Walker, Division of Interventional Radiology, Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, United States
Author contributions: Sheth RA collected and analyzed the data and drafted the manuscript; Feldman AS, Paul E, Thiele EA and Walker TG provided analytical oversight; Walker TG designed and supervised the study; Feldman AS, Paul E, Thiele EA and Walker TG revised the manuscript for important intellectual content; all authors have read and approved the final version to be published.
Institutional review board statement: The study was reviewed and approved by the Massachusetts General Hospital Institutional Review Board.
Informed consent statement: Informed consent was waved in this retrospective study.
Conflict-of-interest statement: All authors declare no conflicts of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Rahul A Sheth, MD, Assistant Professor, Department of Interventional Radiology, MD Anderson Cancer Center, 1400 Pressler St., FCT14.6000, Houston, TX 77030, United States. rasheth@mdanderson.org
Telephone: +1-713-7450652 Fax: +1-713-7924098
Received: September 29, 2015
Peer-review started: October 2, 2015
First decision: November 4, 2015
Revised: November 26, 2015
Accepted: January 8, 2016
Article in press: January 11, 2016
Published online: March 28, 2016
Peer-review started: October 2, 2015
First decision: November 4, 2015
Revised: November 26, 2015
Accepted: January 8, 2016
Article in press: January 11, 2016
Published online: March 28, 2016
Core Tip
Core tip: Pharmacologic management of tuberous sclerosis complex-associated angiomyolipomas with mammalian target of rapamycin inhibitors can provide substantial tumor volume reduction for the duration of the therapeutic course. This volume reduction impacts all three tissue compartments of the tumor. Unfortunately rebound growth involving all tissue compartments follows shortly after discontinuation of mammalian target of rapamycin (mTOR) inhibitor therapy. The addition of transarterial embolization to mTOR inhibition did not curtail the occurrence of rebound growth.